Shared and separate functions of polo-like kinases and aurora kinases in cancer
- PMID: 21102634
- DOI: 10.1038/nrc2964
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Abstract
Large numbers of inhibitors for polo-like kinases and aurora kinases are currently being evaluated as anticancer drugs. Interest in these drugs is fuelled by the idea that these kinases have unique functions in mitosis. Within the polo-like kinase family, the emphasis for targeted therapies has been on polo-like kinase 1 (PLK1), and in the aurora kinase family drugs have been developed to specifically target aurora kinase A (AURKA; also known as STK6) and/or aurora kinase B (AURKB; also known as STK12). Information on the selectivity of these compounds in vivo is limited, but it is likely that off-target effects within the same kinase families will affect efficacy and toxicity profiles. In addition, it is becoming clear that interplay between polo-like kinases and aurora kinases is much more extensive than initially anticipated, and that both kinase families are important factors in the response to classical chemotherapeutics that damage the genome or the mitotic spindle. In this Review we discuss the implications of these novel insights on the clinical applicability of polo-like kinase and aurora kinase inhibitors.
Similar articles
-
Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.Oncotarget. 2015 Apr 20;6(11):9327-40. doi: 10.18632/oncotarget.3313. Oncotarget. 2015. PMID: 25871386 Free PMC article.
-
Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?Cell Cycle. 2012 Apr 15;11(8):1490-5. doi: 10.4161/cc.19724. Epub 2012 Apr 15. Cell Cycle. 2012. PMID: 22433949 Free PMC article.
-
Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.Expert Rev Anticancer Ther. 2011 Jul;11(7):1115-30. doi: 10.1586/era.11.61. Expert Rev Anticancer Ther. 2011. PMID: 21806334 Review.
-
Non-mitotic functions of polo-like kinases in cancer cells.Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188467. doi: 10.1016/j.bbcan.2020.188467. Epub 2020 Nov 7. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33171265 Review.
-
Polo and Aurora kinases: lessons derived from chemical biology.Curr Opin Cell Biol. 2008 Feb;20(1):77-84. doi: 10.1016/j.ceb.2007.11.008. Epub 2008 Jan 30. Curr Opin Cell Biol. 2008. PMID: 18249108 Review.
Cited by
-
Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.PLoS One. 2013;8(2):e55975. doi: 10.1371/journal.pone.0055975. Epub 2013 Feb 6. PLoS One. 2013. PMID: 23405241 Free PMC article.
-
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.Oncotarget. 2015 Apr 20;6(11):8736-49. doi: 10.18632/oncotarget.3538. Oncotarget. 2015. PMID: 25826089 Free PMC article.
-
FBXW7 is involved in Aurora B degradation.Cell Cycle. 2012 Nov 1;11(21):4059-68. doi: 10.4161/cc.22381. Epub 2012 Oct 24. Cell Cycle. 2012. PMID: 23095493 Free PMC article.
-
β-N-Acetylglucosamine (O-GlcNAc) is a novel regulator of mitosis-specific phosphorylations on histone H3.J Biol Chem. 2012 Apr 6;287(15):12195-203. doi: 10.1074/jbc.M111.315804. Epub 2012 Feb 27. J Biol Chem. 2012. PMID: 22371497 Free PMC article.
-
Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.J Biomed Sci. 2015 Jul 4;22(1):48. doi: 10.1186/s12929-015-0150-2. J Biomed Sci. 2015. PMID: 26141684 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous